These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 22054456)
1. [Signal transduction and its targeting from the cancer molecular genetic platform: applications and perspectives in pulmonary pathology]. Merlio JP Ann Pathol; 2011 Nov; 31(5 Suppl):S40-2. PubMed ID: 22054456 [No Abstract] [Full Text] [Related]
2. [Responses to targeted therapies: lung cancer]. Brambilla E Ann Pathol; 2009 Nov; 29 Spec No 1():S77-80. PubMed ID: 19887261 [No Abstract] [Full Text] [Related]
3. [In practice for the pathologist: practical and technical limitations]. Rochaix P Ann Pathol; 2011 Nov; 31(5 Suppl):S43-5. PubMed ID: 22054457 [No Abstract] [Full Text] [Related]
4. [CRAF, a key player in lung adenocarcinomas induced by K-Ras oncogene]. Francoz S; Dubus P Med Sci (Paris); 2011 Oct; 27(10):820-2. PubMed ID: 22027418 [No Abstract] [Full Text] [Related]
5. [Molecular markers having a prognostic or therapeutic value in cancer]. Brousset P Ann Pathol; 2008 Nov; 28 Spec No 1(1):S69-70. PubMed ID: 18984307 [No Abstract] [Full Text] [Related]
6. Genetically informed lung cancer medicine. Pao W; Iafrate AJ; Su Z J Pathol; 2011 Jan; 223(2):230-40. PubMed ID: 21125677 [TBL] [Abstract][Full Text] [Related]
7. Targeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicine. Dumur CI; Idowu MO; Powers CN Cancer Cytopathol; 2013 Feb; 121(2):61-71. PubMed ID: 22887782 [TBL] [Abstract][Full Text] [Related]
8. Biology-driven phase II trials: what is the optimal model for molecular selection? Andre F; Delaloge S; Soria JC J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554 [No Abstract] [Full Text] [Related]
9. [The bewildering complexity of cancer]. Jordan B Med Sci (Paris); 2011; 27(8-9):781-6. PubMed ID: 21880268 [No Abstract] [Full Text] [Related]
10. Personalized-medicine trials on the rise. Benowitz S J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496 [No Abstract] [Full Text] [Related]
12. Targeted cancer therapy: promise and reality. Klein S; Levitzki A Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951 [TBL] [Abstract][Full Text] [Related]
13. Molecular targeted agents and biologic therapies for lung cancer. Somaiah N; Simon GR J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1758-85. PubMed ID: 22005529 [No Abstract] [Full Text] [Related]
14. From correlation to causality: microarrays, cancer, and cancer treatment. O'Neill GM; Catchpoole DR; Golemis EA Biotechniques; 2003 Mar; Suppl():64-71. PubMed ID: 12664688 [No Abstract] [Full Text] [Related]
16. [Desperately seeking targets]. Jordan B Med Sci (Paris); 2015 Feb; 31(2):214-7. PubMed ID: 25744270 [TBL] [Abstract][Full Text] [Related]
17. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541 [TBL] [Abstract][Full Text] [Related]
18. [Use of molecular genetic analysis in selecting antitumor therapy]. Imianitov EN; Moiseenko VM Vopr Onkol; 2008; 54(2):121-32. PubMed ID: 18522159 [No Abstract] [Full Text] [Related]
19. In search of novel molecular targets in cancer: the diacyglycerol pathways. Lorenzo PS Hawaii Med J; 2004 Oct; 63(10):318-9, 321. PubMed ID: 15570721 [No Abstract] [Full Text] [Related]
20. Interventions that induce modifications in the tumor microenvironment. Bernhard EJ Cancer Radiother; 2011 Aug; 15(5):376-82. PubMed ID: 21571567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]